Smurfit Westrock Shares Drop 6% After 4Q Earnings Miss
Smurfit Westrock shares were down 6% to $50.19 after the company reported fourth-quarter earnings that missed analysts' expectations.
SpringWorks Therapeutics price target raised to $66 from $63 at TD Cowen
TD Cowen analyst Yaron Werber raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $66 from $63 and keeps a Buy rating on the ...
Xilio Therapeutics Shares Surge Premarket on AbbVie Deal
Xilio Therapeutics shares took flight in premarket trading Wednesday after the clinical-stage biotechnology company formed a potentially lucrative collaboration with AbbVie that includes an equity ...
Sutro Biopharma stock hits 52-week low at $1.67 amid market challenges
Sutro Biopharma Inc. (NASDAQ:STRO) shares have tumbled to a 52-week low, touching down at $1.67, as the biopharmaceutical company grapples with a challenging market environment. With a market ...
SpringWorks Therapeutics may be worth around $77 a share in a takeover - analyst
SpringWorks Therapeutics (SWTX) may be acquired by Merck KGaA for $77 per share, representing a potential premium of 92% ...
SolarWinds to be acquired by Turn/River Capital for $18.50 per share
SolarWinds (SWI) announced that it has entered into a definitive agreement to be acquired by Turn/River Capital in an all-cash transaction for ...
SolarWinds spikes as private equity firm moves to acquire and delist
SolarWinds, a Texas-based IT firm, to be acquired by Turn/River Capital in a $4.4B deal, leading to a 20% spike in stock ...